Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 2/20 | 0.31 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31619139 | 1.00 | CYP3A4 (0.38) | CYP3A4TSHRTDP1GABRA1GABRB1 | |
| Boric Acid SCHEMBL2461263 | 0.91 | CYP3A4 (0.37) | CYP3A4TSHRTDP1GABRA1GABRB1 | |
| SCHEMBL585514 | 0.86 | CHRM5 (0.33) | CYP3A4TSHRTDP1KDM1AKDM1B | |
| SCHEMBL25259748 | 0.80 | TDP1 (0.47) | CYP3A4TSHRTDP1GABRA1GABRB1 | |
| SCHEMBL29428923 | 0.79 | MAPT (0.37) | KDM1AKDM1BNPC1ALDH1A1GAA | |
| SCHEMBL29363756 | 0.79 | PDK2 (0.37) | TSHRKDM1AKDM1BNPC1ALDH1A1 | |
| SCHEMBL20303393 | 0.79 | MAPT (0.37) | KDM1AKDM1BNPC1ALDH1A1GAA | |
| SCHEMBL414371 | 0.79 | NMT1 (0.38) | CYP3A4TSHRTDP1KDM1AKDM1B | |
| SCHEMBL263907 | 0.79 | PDK2 (0.37) | TSHRKDM1AKDM1BNPC1ALDH1A1 | |
| SCHEMBL21050751 | 0.75 | GAA (0.46) | CYP3A4KDM1AKDM1BALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113980040-B | Boron-containing asymmetric spiro compound and application thereof in organic electroluminescent device | 吉林大学 | 2024-02-27 | — | — | CN | disclosed |
| US-11581493-B2 | Organic electroluminescence device and condensed polycyclic compound for organic electroluminescence device | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-02-14 | — | — | US | disclosed |
| CN-113980040-A | Boron-containing asymmetric spiro compound and application thereof in organic electroluminescent device | 吉林大学 | 2022-01-28 | — | — | CN | disclosed |
| US-20210175431-A1 | ORGANIC ELECTROLUMINESCENCE DEVICE AND CONDENSED POLYCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENCE DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2021-06-10 | — | — | US | disclosed |
| US-20190322668-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2019-10-24 | — | — | US | disclosed |
| EP-3404028-A1 | METHODS OF MAKING ANTIMICROBIAL COMPOUNDS | Melinta Therapeutics, Inc. (US) | 2018-11-21 | — | — | EP | disclosed |
| EP-2697229-B1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MELINTA THERAPEUTICS INC (US) | 2018-04-04 | — | — | EP | disclosed |
| US-9221827-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20140163049-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | MELINTA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| EP-2697229-A2 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | Melinta Therapeutics, Inc. (US) | 2014-02-19 | — | — | EP | disclosed |
| US-7625949-B2 | Methods for treating retroviral infections | ROCHE PALO ALTO LLC (US) | 2009-12-01 | — | — | US | disclosed |
| EP-1742908-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-11-11 | — | — | EP | disclosed |
| EP-1742908-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-11-11 | — | — | EP | disclosed |
| US-7166738-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2007-01-23 | — | — | US | disclosed |
| US-7166738-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2007-01-23 | — | — | US | disclosed |
| US-7166738-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2007-01-23 | — | — | US | disclosed |
| EP-1742908-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005102989-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-03 | — | — | WO | disclosed |
| US-20050239881-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2005-10-27 | — | — | US | disclosed |
| US-20050239880-A1 | Methods for treating retroviral infections | ROCHE PALO ALTO LLC | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239880-A1 | Methods for treating retroviral infections | CCR5, CD38, CD4 | CYP3A4 2749/4885TSHR 1735/4885TDP1 3293/4885 |
| US-20190322668-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MPO, LPO, CAT | CYP3A4 1470/4885TSHR 4385/4885TDP1 2438/4885 |
| US-20140163049-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | MPO, LPO, CAT | CYP3A4 1470/4885TSHR 4385/4885TDP1 2438/4885 |
| US-20050239881-A1 | Non-nucleoside reverse transcriptase inhibitors | RPP30, PNP, RTF1 | CYP3A4 2342/4885TSHR 1773/4885TDP1 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.